<DOC>
	<DOCNO>NCT00002664</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Colony-stimulating factor G-CSF may increase number immune cell find bone marrow peripheral blood , may help person 's immune system kill tumor cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy plus G-CSF treating patient metastatic colorectal cancer respond treatment fluorouracil .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Colony- Stimulating Factor Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate , duration response , survival treatment monoclonal antibody 17-1A granulocyte-macrophage colony stimulate factor patient colorectal cancer metastatic nonhepatic site refractory fluorouracil . II . Describe toxicity associate regimen . III . Assess quality life patient . OUTLINE : Biological Response Modifier Therapy . Colorectal antigen 17-1A murine monoclonal antibody , MOAB 17-1A , NSC-377963 ; Granulocyte-macrophage colony stimulate factor ( Immunex ) , GM-CSF , NSC-613795 . PROJECTED ACCRUAL : There 30 evaluable patient accrue study approximately 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma colon rectum radiologically confirm metastasis clinically confirm incurability No hepatic CNS metastases Progression follow fluorouracil ( 5FU ) alone modulator ( e.g. , leucovorin , PALA , levamisole , interferon ) Measurable disease outside prior radiotherapy field The following consider measurable : Pleural effusion ascites Osteoblastic lesion evidence disease bone scan alone Progressive irradiated lesion alone Bone marrow involvement Brain metastases Malignant hepatomegaly physical exam alone Chemical marker ( e.g. , CEA ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 16 week Hematopoietic : Absolute neutrophil count least 1,800/mm3 Platelet count least 125,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : No concurrent infection Afebrile least 3 day prior treatment unless fever due tumor No known HIV infection No medical condition precludes protocol participation No second malignancy within 5 year except : Nonmelanomatous skin cancer Curatively treat situ cervical carcinoma No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile woman Blood/body fluid analysis within 7 day prior registration Imaging/exams tumor measurement within 21 day prior registration PRIOR CONCURRENT THERAPY : Biologic therapy : No prior mousebased vaccine monoclonal antibody Chemotherapy : At least 2 week since prior 5FU least 1 week past AGC nadir , whichever later No prior chemotherapy except irinotecan Endocrine therapy : Not specify Radiotherapy : At least 6 month since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>